A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

被引：1
|
作者：
Davis, S. Lindsey [1 ]
Lam, Elaine T. [1 ]
Corr, Bradley R. [1 ]
O'Bryant, Cindy L. [1 ]
Glode, Ashley [1 ]
Adler, Nichole [1 ]
Pitts, Todd M. [1 ]
Tentler, John J. [1 ]
Capasso, Anna [1 ]
Dailey, Kyrie [1 ]
Serkova, Natalie J. [1 ]
Weekes, Colin D. [2 ]
Gustafson, Daniel L. [3 ]
Lieu, Christopher H. [1 ]
Messersmith, Wells A. [1 ]
Leong, Stephen [1 ]
Eckhardt, S. Gail [4 ]
Diamond, Jennifer R. [1 ]
机构：
[1] Univ Colorado, Denver, CO 80202 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Colorado State Univ, Ft Collins, CO 80523 USA
[4] Univ Texas Austin, Austin, TX 78712 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A083
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
    Dees, E. Claire
    Cohen, Roger B.
    von Mehren, Margaret
    Stinchcombe, Thomas E.
    Liu, Hua
    Venkatakrishnan, Karthik
    Manfredi, Mark
    Fingert, Howard
    Burris, Howard A., III
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4775 - 4784
  • [42] A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC)
    Necchi, Andrea
    Raggi, Daniele
    Lo Vullo, Salvatore
    Mariani, Luigi
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Perrone, Federica
    Pelosi, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] DEVELOPMENT OF A PHASE 2 STUDY OF THE AURORA KINASE-A INHIBITOR ALISERTIB (MLN8237) IN PRE-TREATED PATIENTS (PTS) WITH UROTHELIAL CANCER (UC)
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchiano, Alfonso
    Crippa, Flavio
    Togliardi, Elena
    Gianni, Alessandro
    Salvioni, Roberto
    De Braud, Filippo
    ANTICANCER RESEARCH, 2014, 34 (05) : 2662 - 2662
  • [44] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [45] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [46] Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis
    Gangat, Naseema
    Stein, Brady Lee
    Marinaccio, Christian
    Swords, Ronan
    Watts, Justin M.
    Gurbuxani, Sandeep
    Frankfurt, Olga
    Altman, Jessica K.
    Wen, Jeremy Q.
    Farnoud, Noushin
    Famulare, Christopher
    Patel, Akshar
    Tapia, Roberto
    Handlogten, Amy
    Dinh, Yvonne Trang
    Englund, Kristen
    Patel, Shradha
    Nobrega, Juan Carlos
    Tejera, Dalissa
    Thomassen, Amber
    Stein, Harald
    Gao, Juehua
    Ji, Peng
    Rampal, Raajit K.
    Giles, Francis J.
    Tefferi, Ayalew
    Crispino, John D.
    BLOOD, 2018, 132
  • [47] Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC)
    Sarantopoulos, John
    Hahn, Noah M.
    Higano, Celestia S.
    Leonard, E. Jane
    Zhang, Bin
    Zhou, Xiaofei
    Ullmann, Claudio Dansky
    Graff, Julie Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies
    Siddiqi, Tanya
    Frankel, Paul
    Ruel, Chris
    Chen, Robert W.
    Kelly, Kevin R.
    Tuscano, Joseph
    Popplewell, Leslie
    Forman, Stephen J.
    Piekarz, Richard
    Newman, Edward
    BLOOD, 2014, 124 (21)
  • [50] Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC)
    Melichar, B.
    DeMichele, A.
    Adenis, A.
    Bourbouloux, E.
    Tan-Chiu, E.
    Niu, H.
    Schusterbauer, C.
    Ullmann, C. Dansky
    Zhang, B.
    Benaim, E.
    CANCER RESEARCH, 2013, 73
12345